Roche And Remynd Will Target Tau

Roche will work with the Belgian biotech firm Remynd to develop drugs that slow the progression of Parkinson’s and Alz­heimer’s diseases. Deal terms were not disclosed, but Remynd says it will receive research funding and could win more than $600 million in milestone payments under the pact. The companies will initially focus on Remynd small molecules that target the proteins α-synuclein and tau, key players in the neurodegeneration associated with Parkinson’s and Alzheimer’s, respectively. Roche will provide chemistry, lead optimization, and development services for the compounds.